Buffalo, NY, August 24 2022 — ZeptoMetrix®, an Antylia Scientific™ company, launches Recombinant Monkeypox Stock: 0831137. This product is intended to aid laboratories in the evaluation of nucleic acid tests designed to detect certain portions of the Monkeypox virus genome.
Recombinant Monkeypox Stock provides laboratories with a targeted, reliable control for PCR testing. It is the only ready-to-use, whole organism full-process molecular control for Monkeypox. The launch of Recombinant Monkeypox Stock represents an exciting addition to the ZeptoMetrix critical infectious disease product line.
Additionally, this fall ZeptoMetrix will be launching a NATtrol™ Monkeypox external run control. This inactivated whole-organism control will help laboratories monitor the day-to-day performance of their Monkeypox assays.
“At ZeptoMetrix, we strive to develop products that meet the needs of laboratories at the forefront of disease diagnostics,” said Evangeline Gonzalez, Vice President/General Manager of ZeptoMetrix. “It is this philosophy that drove the development of our Recombinant Monkeypox Stock. Our lab partners around the world can count on ZeptoMetrix innovation to help them provide timely and accurate testing during this new public health emergency.”
Find more information on how to order the new Recombinant Monkeypox Stock and additional ZeptoMetrix products at www.zeptometrix.com